Product
Casirivimab + Imdevimab Combination Therapy
1 clinical trial
1 indication
Indication
COVID-19Clinical trial
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19Status: Terminated, Estimated PCD: 2022-01-21